286 related articles for article (PubMed ID: 30315283)
1. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis.
Yip TC; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW; Wong GL
Am J Gastroenterol; 2018 Nov; 113(11):1629-1638. PubMed ID: 30315283
[TBL] [Abstract][Full Text] [Related]
2. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
3. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
Yip TC; Lee HW; Wong VW; Wong GL; Tse YK; Lui GC; Ahn SH; Chan HL
J Gastroenterol Hepatol; 2020 Sep; 35(9):1610-1618. PubMed ID: 32032974
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
[TBL] [Abstract][Full Text] [Related]
6. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
[TBL] [Abstract][Full Text] [Related]
8. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
9. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
10. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
11. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
[TBL] [Abstract][Full Text] [Related]
12. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
13. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
Elefsiniotis I; Buti M; Jardi R; Vezali E; Esteban R
Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
[TBL] [Abstract][Full Text] [Related]
15. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
16. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
17. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
18. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
19. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis.
Chen PC; Chen BH; Huang CH; Jeng WJ; Hsieh YC; Teng W; Chen YC; Ho YP; Sheen IS; Lin CY
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1256-1263. PubMed ID: 31498284
[TBL] [Abstract][Full Text] [Related]
20. Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Kim BG; Park NH; Lee SB; Lee H; Lee BU; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
J Viral Hepat; 2018 Dec; 25(12):1565-1575. PubMed ID: 29998592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]